ORIGINAL ARTICLE

Patient Satisfaction and Preference for Metered-Dose Inhalers vs. Dry Powder Inhalers in the Treatment of Obstructive Airway Disease

Sobia Rehman¹, Mehreen Umair², Kaleemullah¹*, Abdul Rehman Azam¹, Mujahid Hussain³, Sohail Akhtar³

2 Department of Pulmonology, Liaquat National Hospital, Karachi, Pakistan.

Correspondence: ku14611@gmail.com

doi: 10.22442/jlumhs.2025.01195

ABSTRACT

OBJECTIVE: To evaluate patient preference for different inhaler devices in the treatment of obstructive airway disease (OAD).

METHODOLOGY: This cross-sectional study was conducted at the Department of Pulmonology, Indus Hospital, Korangi Campus, Karachi, Pakistan during July 2023 to January 2024. Non-probability, consecutive sampling technique was adopted. The inclusion criteria were patients aged 18-70 years, presenting with OADs, irrespective of the duration of disease, and using either metered dose inhaler (MDI) or dry powder inhaler (DPI). Patients who were using pressured MDI (pMDI) were given DPI containing the same drugs at the same dosage for two weeks. Patients who were using DPI were given pMDI containing the same drugs at the same dosage for two weeks. Patients were trained regarding the techniques of inhaler they received, and the patient preference between two inhaler devices was determined by Patient Satisfaction and Preference Questionnaire (PASAPQ). Data analysis was performed using "IBM-SPSS Statistics", version 26.0.

RESULTS: In a total of 100 patients, the mean age was 51.64 ± 13.52 years. There were 59 (59.0%) male patients. Forty-nine percent patients had COPD whereas asthma was present in 50 (51.0%). Out of 100 patients, 50 (50%) each were using MDI and DPI inhalers. The mean PASAPQ scores were significantly higher in terms of satisfaction (p=0.0002), performance (p=0.0002), and convenience (p=0.0374) domains for DPI inhalers.

CONCLUSION: The DPI inhalers were associated with higher levels of satisfaction, performance, and convenience compared to MDI inhalers in the management of OAD.

KEYWORDS: Obstructive airway disease, asthma, chronic obstructive pulmonary disease, metered-dose inhaler, dry powder inhaler.

¹Department of Pulmonology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan

³ Department of Pulmonology, The Indus Hospital, Karachi, Pakistan.

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) and asthma are classified as obstructive airway diseases (OAD) but have distinct pathophysiological mechanisms. COPD is characterized by airway and alveolar destruction and chronic inflammation caused by exposure to harmful particles, such as tobacco smoke. In contrast, asthma is primarily marked by airway hyper-responsiveness and inflammation triggered by various environmental stimuli¹. Globally, both conditions present significant public health challenges. "World Health Organization (WHO)" reports that approximately 235 million people are currently affected by asthma, while around 65 million people suffer from moderate to severe COPD. In Pakistan, the prevalence rates for asthma and COPD are estimated at 13.3% and 13.8%, respectively, highlighting a substantial healthcare burden in the region²⁻⁴.

The main treatment options in OADs are bronchodilators and steroids, while antibiotics are needed infrequently. Bronchodilators are usually delivered to the airways by inhalation. Multiple inhaler devices are available in the market including "metered-dose inhalers (MDI)" and "dry powder inhalers (DPI)" ⁵. The mechanism of drug delivery in MDI is via pressure generation after physical inhaler actuation, enabling the particles to be dispensed. In DPIs, the patient drives the inhalation of particles via inspiration⁵. Learning a good inhaler technique has a significant impact on patient outcomes.⁶ Incorrect technique, which leads to reduced drug delivery, affects lung function measures and exercise tolerance⁴ and is associated with poorer disease outcomes⁵.

Patient preference is an important component of device selection because it influences compliance and adherence to therapy and, hence, can improve long-term outcomes^{6,7}. A study showed that on the "Patient Device Experience Assessment Scale (PDEA)", patients gave Pulmicort Turbuhaler a considerably higher rating for usability than pMDIs $(p=0.0005)^8$. Another study conducted in France regarding identifying preferences for convenience-related inhaler features reported that patient preference was most influenced by the form of the inhaler, the dose counter, and its reusability. The inhalers mostly preferred were L-shaped. Reusable inhalers and inhalers with dose counters had preference, and the findings were notworthy⁹. Another research showed that the mean satisfaction with convenience (based on PASAPQ) of pMDI as 34.4 ± 4.8 and that of Turbuhaler (DPI) as 36.5 ± 4.1 .¹⁰

The literature showed that different ways, multiple forms of drugs, from different populations have been used to assess patient preferences. In Pakistan, the available literature is insufficient to address the local population's preferences between various sorts of inhaler devices so the present study was planned. This study aimed to evaluate patient preference for different inhaler devices in the treatment of OAD.

METHODOLOGY

This was a cross-sectional (descriptive) study, executed at the Department of Pulmonology, Indus Hospital, Korangi Campus, Karachi, during the period of July 2023 to January 2024, after obtaining prior approval from the "Institutional Review Board" (letter number: IRD IRB 2019 20 005, dated: 11-Feb-2020). The inclusion criteria were patients of either gender, aged 18-70 years, presenting with OADs (COPD, asthma), irrespective of the duration of disease, and using DPI or MDI devices. The exclusion criteria were patients with acute exacerbations of obstructive airway disease. Those with cognitive dysfunctions or communication issues, including language barriers and the inability to understand either procedure or technique or both, were also excluded. The individuals who were experiencing progressive and persistent symptoms such as shortness of breath and productive cough and their spirometry showed post-bronchodilator ratio of <70% predicted and irreversible airflow limitation through their lungs were labeled as COPD patients. Patients were informed about the objectives and safety aspects related to this study prior to its execution. Patients received assurances on the privacy of the data they submitted, and formal informed and written consents were obtained. A sample size of 100 was calculated, considering the mean satisfaction with convenience (based on PASAPQ) of pMDI as 34.4±4.8 and that of Turbuhaler (DPI) as 36.5 ± 4.1 ,¹⁰ with the level of significance at 5% and the power of the test at 80%. A non-probability consecutive sampling technique was implemented for sample selection.

After recording the necessary demographics like age, sex, and smoking history, patient preference for the inhaler devices was also inquired about. Patients who were using pMDI (a device that facilitates patient-independent aerosolization but requires satisfactory coordination upon actuation) containing Formoterol-Budesonide were given DPI (a device that is convenient and lightweight but relies upon patient inhalation technique to aerosolize the drug powder) containing the same drugs at the same dosage for two weeks. Patients who were using DPI containing Formoterol-Budesonide were given pMDI containing the same drugs at the same dosage for two weeks. Patients were trained regarding the techniques of inhaler they received, and the patient preference between two inhaler devices was determined by a tool called PASAPQ. The PASAPQ is a simple-to-understand multi-item questionnaire used to assess patients with asthma and COPD regarding their preferences and level of satisfaction with respiratory inhalation devices⁷. It was designed especially to gauge preferences and levels of satisfaction with various inhaler devices. The total score was computed using thirteen satisfaction questions. The performance domain was made up of questions 1 to 5, 10, and 11, and the convenience domain was constructed of questions 6 to 9, 12, and 13. The overall patient satisfaction score was investigated in Question 14. On a seven-point rating system, (1 represented extreme dissatisfaction, 2 dis-satisfaction, 3 slightly unsatisfied, 4 neither unhappy nor satisfied, 5 somewhat satisfied, 6 satisfied, and 7 represented extreme satisfaction) were used to indicate responses to all questions. The total of the items in each domain was converted to a 0-100 points scale in order to get the domain scores. All relevant study data were gathered and documented on a specially designed profroma by the researchers themselves. Data analysis was performed using "IBM-SPSS Statistics", version 26.0. The quantitative variables were expressed by calculating means and the standard deviation. The categorical variables were presented in the form of frequency and percentage. Independent sample t-test was used to compare PAASAPQ scores between different study variables, taking p<0.05 as significant.

RESULTS

In a total of 100 patients, the mean and standard deviation for age, height, weight, and BMI were noted as 51.64 ± 13.52 years (ranging from 20-70 years), 158.67 ± 10.52 cm (ranging from 150-190 cm), 58.32 ± 17.34 kg (ranging from 45-90 kg), and 28.85 ± 3.34 kg/m² (ranging from 23-33 kg/m²), respectively. The frequency distribution of age showed that 71 (71.0%) patients were in the age group between 18-45 years. There were 59 (59.0%) male and 41 (41.0%) female patients. Evaluation about the types of OAD showed that 49 (49.0%) patients had COPD whereas asthma was present in 50 (51.0%) asthma. Smoking status was positive in 49 (49.0%) patients. Characteristics of cases are shown in **Table I**. Out of 100 patients, 50 (50%) each were using MDI and DPI inhalers. The mean PASAPQ

Sources were significantly higher in terms of satisfaction (p=0.0002), performance (p=0.0002), and convenience (p=0.0374) domains for DPI inhalers and the details are shown in **Table II**. Stratification with respect to age (p=0.4312), gender (p=0.8168), type of OAD (p=0.8802), and smoking status (p=0.5780) did not show any significant differences in terms of mean PASAPQ satisfaction scores and the details are shown in **Table III**.

Table I: Frequency distribution of demographic and clinical characteristics of patients with obstructive airway disease (n=100)

Study variables		Frequency (% age)
Age (years)	18-45	29 (29%)
	46-70	71 (71%)
Gender	Male	59 (59%)
	Female	41 (41%)
Type of OAD	COPD	49 (49%)
	Asthma	51 (51%)
Smoking status	Yes	49 (49%)
	No	51 (51%)
Type of inhaler	Metered-dose inhaler	50 (50%)
	Dry powder inhaler	50 (50%)

Table II: Mean Patient Satisfaction Scores According to Type of Inhaler (n=100)

Mean PASAPQ scores	Metered-dose inhaler	Dry powder inhaler	P-value
Patient satisfaction	72.70±6.36	76.48±2.90	0.0002
Performance domain	37.16±5.51	40.48±2.32	0.0002
Convenience domain	35.54±1.19	36.00 ± 0.98	0.0374

Table III: Age, Gender, Type of OAD, and Smoking Status Stratification Considering Mean Patient Satisfaction Scores (n=100)

Characteristics		Mean and standard deviation	P-value
Age (years)	18-45	75.24±4.57	0.4312
	46-70	74.32±5.54	
Gender	Male	74.69±5.19	0.8168
	Female	74.44±5.44	
Type of OAD	COPD	74.67±4.59	0.8802
	Asthma	74.51±5.89	
Smoking status	Yes	74.29±5.47	0.5780
	No	74.88±5.10	

DISCUSSION

The mean PASAPQ satisfaction scores were 72.70±6.36 and 76.48±2.90 in patients who used MDI inhalers and DPI inhalers, favoring DPI inhalers significantly (p=0.0002). Contoli et al. ¹¹ found that the majority of patients were generally satisfied with their DPI devices; while those experiencing a higher burden of asthma symptoms reported lower levels of satisfaction with their DPIs. A study involved 1443 patients and revealed that overall satisfaction of patients with their inhaler was closely linked with treatment compliance (p < 0.001). Moreover, male gender (p < 0.05) and fewer maintenance drugs (p < 0.001) were also associated with compliance. It was also found that reductions in exacerbations were directly associated with inhaler satisfaction $(R^2=0.03; p<0.001)^{12}$. Another study showed that asthma patients had a notably higher satisfaction level with the inhalers (p < 0.001) and were more satisfied on most (70%) items¹³. Regardless of the level of adherence or the type of nonadherence, asthmatic patients generally reported high satisfaction with their inhalers. Previous research has shown that factors such as younger age, effective disease control, prior inhaler training, and absence of unintentional non-adherence are significantly associated with greater inhaler satisfaction. However, this study did not identify any specific factors influencing patient satisfaction scores¹⁴. There is a need of proactive surveillance and improved training regarding the inhalation method in order to enhance clinical outcomes, medication adherence, and patient satisfaction¹⁵. Beeh et al.¹⁶ conducted a study that found comparable efficacy and safety between similar formulations of DPI and pressurized MDI in patients with COPD. These findings support the use of DPI as a viable treatment option, offering flexibility for both patients and healthcare providers.

Many kinds of inhaler devices are available for the management of OAD, each with unique features. It is essential to select a device that aligns patient's need, preference, and satisfaction while ensuring adequate disease control. Although no single device may be perfect for all patients, the broad range of options allows for the identification of a suitable device for each patient. Education is crucial, both for patients to develop proper inhaler techniques and for healthcare providers to make informed decisions, ensuring optimal device selection and effective use. Inhalable medications designed for individuals with asthma and COPD can be perplexing, even for healthcare professionals, owing to the plethora of available devices, each operating on different principles¹⁷⁻¹⁹. The DPI emerge as a valuable option for the majority of patients dealing with asthma or COPD. However, the widespread issue of suboptimal adherence and errors in device handling necessitates ongoing vigilance and patient education to navigate the potential pitfalls associated with inhalation therapy²⁰. Researchers have also demonstrated that patients who receive special guidance and training from physicians show better satisfaction scores for their inhaler devices so it is imperative that proper guidance and training be provided to all affected individuals²¹.

Effective management of asthma and COPD relies on the appropriate selection and use of inhalation devices^{22,23}. However, challenges such as disease severity, pulmonary function, manual dexterity, and comorbidities like arthritis can complicate inhaler use, and no single device suits all patients²⁴. In addition to these factors, patient engagement and satisfaction are crucial for adherence. Issues with inhaler use are particularly evident in children and older adults, making tailored device selection essential. Common inhalers include nebulizers, pressurized MDIs, DPIs, and soft mist inhalers. Each offers distinct technical properties, so a personalized approach to selecting the most suitable device can improve outcomes and adherence.

The major limitations of this research included a single center study. More studies involving multiple study sites and large number of OAD patients should be conducted to further analyze patients preferences regarding various inhaler devices used in the contemporary

J Liaquat Uni Med Health Sci April 29, 2025 doi: 10.22442/jlumhs.2025.01195 Page 5 of 8

world. There is also a need to guage the impact of patient satisfaction with inhaler devices on the disease outcomes of OAD.

CONCLUSION

The DPI inhalers are associated with higher levels of satisfaction, performance, and convenience compared to MDI inhalers in the management of obstructive airway disease. Patient education is vital for optimal disease management and proper inhaler technique, while healthcare professionals should be knowledgeable about the devices they prescribe and provide comprehensive support to patients in clinical practice.

Acknowledgements: The authors are thankful to M. Aamir Latif (RESnTEC) for his assistance in statistical analysis of this research.

Ethical permission: IRD Global Limited, IRB letter No. IRD_IRB_2019_20_005.

Conflict of Interest: No conflicts of interest, as stated by authors.

Financial Disclosure / Grant Approval: No funding agency was involved in this research.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publically.

AUTHOR CONTRIBUTION

Rehman S: Data Collection, Drafting, responsible for data, approved for publication.

Umair M: Data Collection, Data Analysis, critical revisions, approved for publication.

Kaleemullah: Literature Review, Drafting, Critical Revisions, responsible for data, approved for publication.

Azam AR: Literature Review, drafting, critical revisions, responsible for data, approved for publication.

Hussain M: Conceptual framework, Data Interpretation, proof reading, critical revision, approved for publication.

Akhtar S: Conception, Proof Reading, critical revisions, approved for publication.

REFERENCES

- 1. Park HS, Yoon D, Lee HY, Ban GY, Ming SWY, Jie JLZ et al. Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. Respirology. 2019; 24(10): 972-979. doi:10.1111/resp.13559.
- Masjedi M, Ainy E, Zayeri F, Paydar R. Assessing the prevalence and incidence of asthma and chronic obstructive pulmonary disease in the Eastern Mediterranean region. Turk Thorac J. 2018; 19(2): 56-60. doi:10.5152/TurkThoracJ.2018.17051. Erratum in: Turk Thorac J. 2018 Jul;19(3):158.
- 3. Almzaiel AJ, Al-Ameri AMJ, Tariq R. Role of Apo E and Superoxide Dismutase in Patients with Obstructive Lung Diseases. J Contemp Med Sci. 2017; 3(9): 189-192.
- Rao C, Subhankar S, Alone V, Prasad DD, Sabat J. Study of Prevalence and Pattern of Infections in Acute Exacerbations of Obstructive Airway Disease. Iraq Med J. 2020; 4(3): 85-89. doi: 10.22317/imj.v4i3.879.
- Mannan H, Foo SW, Cochrane B. Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices. BMC Res Notes. 2019; 12(1): 94. doi: 10.1186/s13104-019-4123-5.
- 6. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010; 181(6): 566-577. doi: 10.1164/rccm.200906-0907OC.
- Miravitlles M, Montero-Caballero J, Richard F, Santos S, Garcia-Rivero JL, Ortega F et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11: 407-415. doi: 10.2147/COPD.S91118.
- Welch MJ, Nelson HS, Shapiro G, Bensch GW, Sokol WN, Smith JA et al. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler versus pressurized metered-dose inhalers. J Aerosol Med. 2004; 17(2): 129-139. doi: 10.1089/0894268041457174.
- Chouaid C, Germain N, De Pouvourville G, Aballéa S, Korchagina D, Baldwin M et al. Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. Curr Med Res Opin. 2019; 35(5): 785-792. doi: 10.1080/03007995.2019.1574507.
- Jahedi L, Downie SR, Saini B, Chan HK, Bosnic-Anticevich S. Inhaler technique in asthma: how does it relate to patients' preferences and attitudes toward their inhalers? J Aerosol Med Pulm Drug Deliv. 2017; 30(1): 42-52. doi: 10.1089/jamp.2016.1287.
- Contoli M, Barile S, Nudo E, Guastalla D, Braido F. Exploring quality of life and satisfaction with treatment in asthmatic patients receiving dry powder inhalers: a multinational survey. J Asthma. 2022; 59(7): 1473-1483. doi: 10.1080/02770903.2021.1923739.
- 12. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014; 108(2): 358-365. doi: 10.1016/j.rmed.2013.09.021.
- 13. Plaza V, Giner J, Curto E, Alonso-Ortiz MB, Orue MI, Vega JM et al. Determinants and Differences in Satisfaction with the Inhaler Among Patients with Asthma or COPD. J Allergy Clin Immunol Pract. 2020; 8(2): 645-653. doi: 10.1016/j.jaip.2019.09.020.
- 14. Shayo GA, Omary A, Mugusi F. Inhaler Non-Adherence, Associated Factors and Asthma Control among Asthma Patients in a Tertiary Level Hospital in Tanzania. East Afr Health Res J. 2022; 6(1): 78-85. doi: 10.24248/eahrj.v6i1.682.

- 15. Ohbayashi H, Kudo S, Ishikawa M. Inhaler Operability and Patient Satisfaction Regarding Genuair® and Respimat® Inhalers for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Study. Pulm Ther. 2017; 3: 173-185. doi: 10.1007/s41030-017-0038-2.
- 16. Beeh KM, Kuna P, Corradi M, Viaud I, Guasconi A, Georges G. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial. Int J Chron Obstruct Pulmon Dis. 2021; 16: 79-89. doi: 10.2147/COPD.S291030.
- Levy ML, Carroll W, Alonso JLI, Keller C, Lavorini F, Lehtimäki L. Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes. Adv Ther. 2019; 36(10): 2547-2557. doi: 10.1007/s12325-019-01066-6.
- Mahler DA, Halpin DMG. Personalizing Selection of Inhaled Delivery Systems in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2023; 20(10): 1389-1396. doi: 10.1513/AnnalsATS.202304-384CME.
- 19. Bivolaru S, Constantin A, Vlase CM, Gutu C. COPD Patients' Behaviour When Involved in the Choice of Inhaler Device. Healthcare (Basel). 2023; 11(11): 1606. doi: 10.3390/healthcare11111606.
- 20. de Oliveira MVC, Pizzichini E, da Costa CH, Fritscher CC, Vianna EO, Teixeira PJZ et al. Evaluation of the preference, satisfaction and correct use of Breezhaler® and Respimat® inhalers in patients with chronic obstructive pulmonary disease–INHALATOR study. Respir Med. 2018; 144: 61-67. doi: 10.1016/j.rmed.2018.10.006.
- Valladales-Restrepo LF, Saavedra-Navia JC, Montezuma-Casanova CA et al. Satisfaction with and Use of Inhalation Devices in Patients with Bronchial Asthma. J Aerosol Med Pulm Drug Deliv. 2022; 35(6): 313-320. doi: 10.1089/jamp.2022.0027.
- 22. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019; 15: 461-472. doi: 10.2147/TCRM.S160365.
- 23. Usmani OS, Levy ML. Effective respiratory management of asthma and COPD and the environmental impacts of inhalers. NPJ Prim Care Respir Med. 2023; 33(1): 24. doi: 10.1038/s41533-023-00346-7.
- 24. Roche N, Devillier P, Berger P, Bourdin A, Dusser D, Muir JF et al. Individual trajectorybased care for COPD: getting closer, but not there yet. ERJ Open Res. 2021; 7(4): 00451-2021. doi: 10.1183/23120541.00451-2021.